Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Gynecologic Oncology

• Publication date

  2013-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ygyno.2013.03.001PMID 23500084
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.

  2012cited by this paper
• Serum HE4 as a Useful Biomarker in Discriminating Ovarian Cancer From Benign Pelvic Disease

  2012cited by this paper
• Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses.

  2012cited by this paper
• Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.

  2012cited by this paper
• Diagnostic value of HE4 for ovarian cancer: a meta-analysis

  2012cited by this paper
• Diagnostic Value of Serum Human Epididymis Protein 4 (HE4) in Ovarian Carcinoma: A Systematic Review and Meta-Analysis

  2012cited by this paper
• Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass

  2012cited by this paper
• Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and ca125 in predicting epithelial ovarian cancer: A meta-analysis

  2012cited by this paper
• HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm

  2011cited by this paper
• Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass

  2011cited by this paper
• HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases

  2011cited by this paper
• Serum Human Epididymis Protein 4 and Risk for Ovarian Malignancy Algorithm as New Diagnostic and Prognostic Tools for Epithelial Ovarian Cancer Management

  2011cited by this paper
• Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases.

  2011cited by this paper
• No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.

  2011cited by this paper
• Comprehensive Serum Profiling for the Discovery of Epithelial Ovarian Cancer Biomarkers

  2011cited by this paper
• The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses

  2011cited by this paper
• HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm.

  2011cited by this paper
• Reducing time to diagnosis does not improve outcomes for women with symptomatic ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

  2011cited by this paper
• The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?

  2011influential reference
• Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population

  2011cited by this paper
• A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.

  2009cited by this paper
• Triage of ovarian masses

  2008cited by this paper
• Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer

  2008cited by this paper
• Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.

  2008cited by this paper
• Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome

  2008cited by this paper
• Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations.

  2007cited by this paper
• Comprehensive analysis of HE4 expression in normal and malignant human tissues

  2006cited by this paper
• The Incidental Postmenopausal Adnexal Mass

  2006cited by this paper
• Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study.

  2005cited by this paper
• Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.

  2005cited by this paper
• A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer

  1991cited by this paper
• A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors.

  1991cited by this paper
• A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer

  1990cited by this paper
• Reactivity of a monoclonal antibody with human ovarian carcinoma.

  1981cited by this paper

• Diagnostic value of the Risk of Ovarian Malignancy Algorithm (ROMA) index in the detection of ovarian cancer in postmenopausal women: a systematic review and meta-analysis

  2025cites this paper
• Diagnostic Use of the Combination of CA72‐4 and Tumor Volume in Mucinous Ovarian Tumors

  2025cites this paper
• Surgical Management of Ovarian Masses in Children: A Comparative Analysis by Pediatric Surgeons and Gynecologists at Two Academic Hospitals in Johannesburg

  2025cites this paper
• Ovarian cancer detection from mutual information-ranked clinical biomarkers using an explainable attention-based residual multilayer perceptron

  2025cites this paper
• Epidemiological characteristics of suspected adenomyosis in the Chinese physical examination population: a nested case-control study

  2024cites this paper
• Recent advances in surface plasmon resonance for the detection of ovarian cancer biomarkers: a thorough review

  2024cites this paper
• Evaluating the role of wound‐healing genes in conjunction with stool routine and serum tumor markers for colorectal cancer diagnosis and prognostic implications

  2024cites this paper
• Artificial intelligence and allied subsets in early detection and preclusion of gynecological cancers.

  2023cites this paper
• Applications of artificial intelligence (AI) in ovarian cancer, pancreatic cancer, and image biomarker discovery.

  2022cites this paper
• Nectin-4 as Blood-Based Biomarker Enables Detection of Early Ovarian Cancer Stages

  2022cites this paper
• Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis

  2021cites this paper
• Correlation of Preoperative HE-4 and CA125 with Ovarian Cancer Staging in Ahvaz Imam Khomeni Hospital

  2020cites this paper
• Primary appendiceal adenocarcinoma presenting as advanced ovarian cancer: a case report

  2020cites this paper
• The Efficacy of HE4 and ROMA in Prediction of Ovarian Malignancy in Comparison to CA-125 and RMI

  2020cites this paper
• بررسی میزان صحت سطوح سرمی پیش از جراحی CA-125 وHE-4 در مرحلهبندی جراحی بیماران مبتلا به سرطان تخمدان مراجعه کننده به کلینیک زنان بیمارستان امام خمینی اهواز

  2020cites this paper
• Performance of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) in diagnosis of ovarian cancer: a systematic review and meta-analysis

  2020cites this paper
• Role of Tumor Markers

  2019cites this paper
• CA 125 , YKL-40 , HE-4 and Mesothelin : a new serum biomarker combination in discrimination of benign and malign epithelial ovarian tumor CA 125 , YKL-40 , HE-4 ve Mezotelin : Benign ve Malign Epitelial

  2019cites this paper
• CA125, YKL-40, HE-4 and Mesothelin: a new serum biomarker combination in discrimination of benign and malign epithelial ovarian tumor

  2019cites this paper
• Application of Artificial Intelligence for Preoperative Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer Based on Blood Biomarkers

  2019cites this paper
• Expresión del receptor de factor de crecimiento epidérmico en cáncer de ovario

  2018cites this paper
• Assessment of Diagnostic Values among CA-125, RMI, HE4, and ROMA for Cancer Prediction in Women with Nonfunctional Ovarian Cysts

  2018cites this paper
• Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

  2018cites this paper
• Utilidad de la Proteína Epididimal Humana 4 (HE4) en la detección de Cáncer de ovario.

  2018cites this paper
• Utilization of Tumor Markers in Adnexal Masses: A Review of Current Literature

  2018cites this paper
• Clinical applications in gynaecological cancer

  2017cites this paper
• Difficulty in diagnosis and different prognoses between colorectal cancer with ovarian metastasis and advanced ovarian cancer: An empirical study of different surgical adoptions.

  2017cites this paper
• A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer an international multicenter study of women with an ovarian mass

  2017cites this paper
• Adjustment of serum HE4 to reduced glomerular filtration and its use in biomarker-based prediction of deep myometrial invasion in endometrial cancer

  2017cites this paper
• Adjustment of serum HE4 to reduced glomerular filtration and its use in biomarker-based prediction of deep myometrial invasion in endometrial cancer

  2017cites this paper
• Syddansk Universitet Adjustment of serum HE 4 to reduced glomerular filtration and its use in biomarker-based prediction of deep myometrial invasion in endometrial cancer

  2017cites this paper
• Top-down nanofabrication of silicon nanoribbon field effect transistor (Si-NR FET) for carcinoembryonic antigen detection

  2017cites this paper
• 1st Evidence-based Italian Consensus Conference on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Ovarian Cancer

  2017cites this paper
• Short O-GalNAc glycans: regulation and role in tumor development and clinical perspectives.

  2016cites this paper
• Diagnosis and Management of Adnexal Masses.

  2016cites this paper
• HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer

  2016cites this paper
• Clinical significance of detecting CEA , CA 199 , AFP , HCG , CA 153 , CA 125 in postoperative treatment of patients with ovarian cancer

  2016cites this paper
• Comparing the Copenhagen Index (CPH-I) and Risk of Ovarian Malignancy Algorithm (ROMA): Two equivalent ways to differentiate malignant from benign ovarian tumors before surgery?

  2016cites this paper
• The development of dual-label time-resolved fluorescence immunoassay (TRFIA) for screening of ovarian cancer based on simultaneous detection of human epididymis protein-4 and cancer antigen 125

  2016cites this paper
• Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis

  2016cites this paper
• Alkaline phosphatase labeled antibody-based electrochemical biosensor for sensitive HE4 tumor marker detection

  2015cites this paper
• Discrepant clinicopathologic characteristics and HE4 performance in type I and type II epithelial ovarian cancer.

  2015cites this paper
• The Diagnostic Value of Transvaginal Sonograph (TVS), Color Doppler, and Serum Tumor Marker CA125, CEA, and AFP in Ovarian Cancer

  2015cites this paper
• A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - An international multicenter study in women with an ovarian mass.

  2015cites this paper
• Significance of adding progesterone to the Risk of Ovarian Malignancy Algorithm for early stage ovarian cancer detection in patients with a pelvic mass: A single-center case-control study.

  2015cites this paper
• Diagnostic value of CA125, HE4, ROMA and logistic regression model in pelvic mass diagnostics - our experience.

  2015cites this paper
• Expression and Diagnostic Value of HE4 in Pancreatic Adenocarcinoma

  2015cites this paper
• HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses ‐ a prospective comparison in the pre‐operative evaluation of pelvic masses in an Australian population

  2015cites this paper
• Detection of glyco‐mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours

  2015cites this paper
• Plasma fibrinogen levels in patients with benign and malignant ovarian tumors.

  2015cites this paper
• Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis

  2014cites this paper
• The Emerging Role of HE4 in the Evaluation of Advanced Epithelial Ovarian and Endometrial Carcinomas

  2014cites this paper
• Targeting Signaling Pathways in Epithelial Ovarian Cancer

  2013cites this paper
• Differentiating stage I epithelial ovarian cancer from benign disease in women with adnexal tumours using biomarkers or the ROMA algorithm.

  2013cites this paper
• Candidate microRNA biomarkers in human epithelial ovarian cancer: systematic review profiling studies and experimental validation

  2013cites this paper
• Pattern of tissue expression of CA-125 and HE4 in primary epithelial ovarian tumours and correlation with serum CA-125 levels.

  2013cites this paper
• The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.

  2013cites this paper
• Differentiating stage I epithelial ovarian cancer from benign disease in women with adnexal tumors using biomarkers or the ROMA algorithm.

  2013cites this paper
• Ovarialkarzinom

  2013cites this paper
• Application of Arti fi cial Intelligence for Preoperative Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer Based on Blood Biomarkers

  year unknowncites this paper
• Applications of artificial intelligence (AI) in ovarian cancer, pancreatic cancer, and image biomarker discovery

  year unknowncites this paper